Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'".
Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, Rea W, Ventriglia EN, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter GC, Weinshenker D, Zarate CA Jr, Casadó V, Baumann MH, Pardo L, Ferré S, Michaelides M. Levinstein MR, et al. Among authors: zarate ca jr. Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02864-3. Online ahead of print. Mol Psychiatry. 2024. PMID: 39639176 No abstract available.
Clinical indicators of the suicide crisis and response to ketamine.
Ballard ED, Neely L, Waldman L, Greenstein D, Zarate CA Jr. Ballard ED, et al. Among authors: zarate ca jr. J Affect Disord. 2024 Nov 29;372:126-133. doi: 10.1016/j.jad.2024.11.080. Online ahead of print. J Affect Disord. 2024. PMID: 39617360
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial.
Machado-Vieira R, Jones GH, Courtes AC, Ruiz AC, Vecera CM, Henter ID, Lane SD, Zarate CA Jr, Soares JC. Machado-Vieira R, et al. Among authors: zarate ca jr. J Affect Disord. 2024 Dec 15;367:281-285. doi: 10.1016/j.jad.2024.08.183. Epub 2024 Aug 28. J Affect Disord. 2024. PMID: 39214377 Clinical Trial.
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.
Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Kowalski K, Barksdale CT, Gufford BT, Awan A, Sancho AR, Moore MC, Berrada K, Cogan GB, DeLaRosa J, Radcliffe J, Pao M, Kennedy M, Lawrence Q, Goldfeder L, Amanfo L, Zanos P, Gilbert JR, Morris PJ, Moaddel R, Gould TD, Zarate CA Jr, Thomas CJ. Raja SM, et al. Among authors: zarate ca jr. Clin Pharmacol Ther. 2024 Nov;116(5):1314-1324. doi: 10.1002/cpt.3391. Epub 2024 Jul 25. Clin Pharmacol Ther. 2024. PMID: 39054770 Clinical Trial.
Esketamine in depression: putative biomarkers from clinical research.
Johnston JN, Zarate CA Jr, Kvarta MD. Johnston JN, et al. Among authors: zarate ca jr. Eur Arch Psychiatry Clin Neurosci. 2024 Jul 13. doi: 10.1007/s00406-024-01865-1. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38997425 Review.
385 results